Dilon cooperation with GE distributes its molecular breast imaging system

A bladder cancer drug clinical trials from the University of Hawaii Cancer Center has been getting closer to FDA's approval criteria, and this new drug called interleukin-15 Super antagonist compound (ALT-803) can be combined with BCG, is expected to Effective treatment of non-muscle invasive bladder cancer patients, rather than muscle invasive bladder cancer is the most common type of bladder cancer.Researchers Charles Rosser said the last time the FDA approved the drug or bladder cancer almost 20 years ago, the thing, the current bladder cancer therapy, and not much progress since the 1980s, BCG has been used for medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.Phase II clinical trials have recently been approved by the audit department and the FDA system, the first patient phase II clinical trials for the October 15, 2015 recruited, and the clinical trial will include 124 participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015 summer researchers completed the nine participants in Phase I clinical trials, at least 20% of participants expect the recurrence of bladder cancer cases will appear, but as of now, and no patients had cancer recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.